Steroid management in giant cell arteritis

被引:90
|
作者
Chan, CCK [1 ]
Paine, M [1 ]
O'Day, J [1 ]
机构
[1] Royal Victorian Eye & Ear Hosp, Dept Neuroophthalmol, Melbourne, Vic 3002, Australia
关键词
D O I
10.1136/bjo.85.9.1061
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aim-Ocular involvement in giant cell arteritis (GCA) is an ophthalmic emergency which, if untreated, can progress to permanent blindness. There is little evidence in the literature to support current protocols for the acute treatment of GCA with steroids. The authors sought to review the effects of intravenous and oral steroids in GCA. Methods-This retrospective study reviewed the records of 100 consecutive patients with biopsy proved giant cell arteritis. 73 patients with visual loss who were treated at the Royal Victorian Eye and Ear Hospital (RVEEH) and St Vincent's Hospital were included in the final series. The authors studied the management of the patients in the first week after presentation, analysing types of treatment, dose, effect on visual acuity, and complications. Results-All the patients except one had visual loss due to anterior ischaemic optic neuropathy (AION). 17 patients (23%) had bilateral eye involvement. Visual acuity improved in 21 of 73 patients (29%) by a mean of two Snellen chart lines after commencement of steroids. There was an increased likelihood of improved vision in the group who had intravenous steroids (40%) compared with those who received oral steroids (13%). In all except four patients (95%) vision remained stable at I month review. Conclusions-Prompt treatment of GCA with steroids leads to improvement of visual acuity in a significant number of cases. Intravenous steroids may offer a greater prospect of improvement compared with oral steroids. A prospective trial comparing intravenous with oral steroids is needed to validate these findings and would not expose elderly patients to unacceptable risks.
引用
收藏
页码:1061 / 1064
页数:4
相关论文
共 50 条
  • [41] Diagnosis and management of giant cell arteritis: Major review
    Simon, Sumu
    Ninan, Jem
    Hissaria, Pravin
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 49 (02): : 169 - 185
  • [42] Optimal management of giant cell arteritis and polymyalgia rheumatica
    Charlton, Rodger
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 173 - 179
  • [43] Giant cell arteritis: reviewing the advancing diagnostics and management
    Bilton, Edward J.
    Mollan, Susan P.
    EYE, 2023, 37 (12) : 2365 - 2373
  • [44] Current management of giant cell arteritis and its complications
    Galli, Elena
    Muratore, Francesco
    Warrington, Kenneth J.
    CURRENT OPINION IN RHEUMATOLOGY, 2024, 36 (05) : 344 - 350
  • [45] Concise guidance: diagnosis and management of giant cell arteritis
    Dasgupta, Bhaskar
    CLINICAL MEDICINE, 2010, 10 (04) : 381 - 386
  • [46] A REGIONAL AUDIT OF THE INVESTIGATION AND MANAGEMENT OF GIANT CELL ARTERITIS
    Little, Jayne
    Sharp, Charlotte A.
    Davies, Edward
    Akram, Qasim
    Bruce, Ellen S.
    Bukhari, Syed
    Coates, Lucy
    Davids, Trixy
    Javed, Saadia
    Juman, Sabrina
    MacPhie, Elizabeth
    McCabe, Paul S.
    Teh, Lee-Suan
    Varughese, Sneha
    Uke, Perpetual
    Shah, Preeti
    Mercer, Louise
    RHEUMATOLOGY, 2018, 57
  • [47] Giant cell arteritis: reviewing the advancing diagnostics and management
    Edward J. Bilton
    Susan P. Mollan
    Eye, 2023, 37 : 2365 - 2373
  • [48] Giant cell arteritis: recent advances and guidelines for management
    Dasgupta, B.
    Hassan, N.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (01) : S62 - S65
  • [49] GIANT CELL ARTERITIS: AN AUDIT OF EARLY RECOGNITION AND MANAGEMENT
    Borg, F.
    Ezeonyegi, A.
    Wong, W. M.
    Riaz, I.
    Gordon, T.
    Dasgupta, B.
    RHEUMATOLOGY, 2009, 48 : I43 - I43
  • [50] Recent advances in the diagnosis and management of giant cell arteritis
    Serling-Boyd, Naomi
    Stone, John H.
    CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (03) : 201 - 207